Grace Hampson

Grace is an economist with a strong interest in value assessment, pricing and reimbursement, and public health economics. She is team leader for OHE’s Policy, Organisation and Incentives in Health Systems Research theme.  

Grace’s work is dedicated to advancing value assessment and healthcare decision-making. Her current research interests include high-value innovative technologies like cell and gene therapies, AMR-targeting drugs and devices, and the economics of environmental sustainability in healthcare and life sciences.  

Grace previously worked developing NICE guidelines and has served as an advisor in economics across NICE’s Clinical Guidelines and Public Health Guidelines committees. Grace holds an MSc in Health Economics from the University of York and an MSc in Nutritional Medicine from the University of Surrey. 

Publications and Insights

• Publication: Taking STRIDES: The value of diagnostics against AMR
• Insight: Pharmacogenomics Testing: A Crucial Piece to Unlocking the Full Value of Medicines
• Publication: Altering the trajectory of HIV in Europe
• Publication: Challenges and Solutions for Budget Impact Analysis of Gene Therapies
• Insight: R&D for new drugs to tackle AMR is a high-return investment for all EU member states
• Insight: Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA
• Insight: Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
• Insight: Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
• Publication: Capturing the Broader Value of Antibiotics
• Insight: OHE’s AMR consultation response
• Publication: Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?
• Publication: Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective
• Bulletin: Unlocking prevention for a healthier society
• Publication: Reimagining Prevention for a Healthier, More Prosperous Society
• Publication: Are Recommendations for HTA of Gene Therapies Being Achieved?
• Insight: New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
• Publication: Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
• Publication: The Lower Drug Costs Now Act and Pharmaceutical Innovation
• Publication: Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
• Publication: Exploring the Financial Sustainability of Gene Therapies
• New: Opportunities to Increase Efficiency in Healthcare
• Publication: Opportunities to Increase Efficiency in Healthcare
• Publication: HTA and Payment Mechanisms for New Drugs to Tackle AMR
• Publication: Public Preferences for Health Gains and Cures: A Discrete Choice Experiment
• Publication: Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions
• Publication: Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market
• Publication: ‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre
• Publication: How can HTA meet the needs of health system and government decision makers?
• Publication: Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies
• Publication: Transferability of HTA
• Publication: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
• Publication: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
• Publication: Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
• Publication: Four Case Studies to Explore the Added Value of Oxford AHSN
• Publication: “New Age” Decision Making in HTA: Is It Applicable in Asia?
• Publication: A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications
• Publication: Dementia: The R&D Landscape